)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Rein Therapeutics
Rein Therapeutics (RNTX) investor relations material
Rein Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary15 May, 2026
Executive summary
Focused on developing therapies for orphan pulmonary and fibrosis indications, with LTI-03 as the lead candidate in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF).
LTI-01 development paused indefinitely to prioritize LTI-03; preclinical programs continue.
First patient dosed in the RENEW Phase 2 trial in March 2026; interim topline data expected Q4 2026.
No revenue from product sales; operations funded by equity, warrants, and debt financings.
Financial highlights
Net loss of $5.8 million for Q1 2026, compared to $5.5 million in Q1 2025.
Operating expenses totaled $5.2 million in Q1 2026, down from $5.6 million in Q1 2025.
Cash and cash equivalents were $4.4 million as of March 31, 2026.
Accumulated deficit reached $407.1 million as of March 31, 2026.
No revenue recognized; all expenses related to R&D and G&A.
Outlook and guidance
Cash on hand plus $53.1 million net proceeds from May 2026 offering expected to fund operations into Q1 2028.
Sufficient funds to complete the Phase 2 RENEW trial of LTI-03.
Continued operating losses expected as clinical development progresses.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Rein Therapeutics
- Biopharma seeks $48M via Nasdaq IPO to advance IPF drug, repay debt, and fund operations.RNTX
Registration filing29 Apr 2026 - LTI-03 advances as a promising, safe IPF therapy with dual antifibrotic and regenerative action.RNTXCorporate presentation22 Apr 2026
- LTI-03 shows strong early safety and efficacy signals for IPF, targeting a major unmet market.RNTXCorporate presentation22 Apr 2026
- Net loss was $49.9M in 2025; LTI-03 Phase 2 trial ongoing, but cash only funds operations into Q2 2026.RNTXQ4 202526 Mar 2026
- LTI-03 demonstrates strong anti-fibrotic and regenerative potential for IPF with favorable safety.RNTXCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026
- LTI-03 reduced key fibrosis biomarkers and was well tolerated in IPF, supporting phase II trials.RNTXStudy Result14 Jan 2026
- Biopharma seeks up to $150M in securities, targeting rare lung diseases; at-the-market deal in place.RNTXRegistration Filing16 Dec 2025
- Shareholders will vote on a director election and executive pay, with enhanced governance and oversight.RNTXProxy Filing2 Dec 2025
- Shareholders will vote on directors, executive pay, and auditor ratification at the 2024 virtual meeting.RNTXProxy Filing2 Dec 2025
Next Rein Therapeutics earnings date
Q2 202613 Aug, 2026
Rein Therapeutics
Next Rein Therapeutics earnings date
Q2 202613 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage